The U.S. Food and Drug Administration granted full approval on Thursday for Moderna’s Spikevax Covid-19 vaccine in children aged six months through 11 years who have at least one medical condition that raises their risk of severe disease. The decision converts the shot’s emergency-use status into a full biologics license, making Spikevax the first Covid vaccine for U.S. children to move beyond emergency authorization. The agency’s label limits use to high-risk youngsters, in line with Health Secretary Robert F. Kennedy Jr.’s May directive that halted routine Covid vaccination recommendations for healthy children. The Centers for Disease Control and Prevention continues to say vaccination remains an option when parents and physicians agree it is needed. Moderna said it expects an updated version of Spikevax to be available for eligible groups ahead of the 2025-26 respiratory virus season. Investors welcomed the news, sending Moderna shares up roughly 2% to $33.45 in pre-market trade.